Professur für Translationale Frauenheilkunde und Geburtshilfe

Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients (2020) Franken A, Honisch E, Reinhardt F, Meier-Stiegen F, Yang L, Jaschinski S, Esposito I, et al. Journal article Prediction and clinical utility of a contralateral breast cancer risk model (2019) Giardiello D, Steyerberg EW, Hauptmann M, Adank MA, Akdeniz D, Blomqvist C, Bojesen SE, et al. Journal article Human leucocyte antigen class i in hormone receptor-positive, HER2-negative breast cancer: Association with response and survival after neoadjuvant chemotherapy (2019) Sinn BV, Weber KE, Schmitt WD, Fasching P, Symmans WF, Blohmer JU, Karn T, et al. Journal article Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy (2019) Hartkopf AD, Mueller V, Woeckel A, Lux MP, Janni W, Ettl J, Belleville E, et al. Journal article, Review article Event Report 11th Scientific Symposium of the AGO TraFo (2019) Banys-Paluchowski M, Wunderle M, Fehm TN, Arnold N, Fasching P Journal article, Editorial The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer (2019) Figlioli G, Bogliolo M, Catucci I, Caleca L, Lasheras SV, Pujol R, Kiiski JI, et al. Journal article Two truncating variants in FANCC and breast cancer risk (2019) Dork T, Peterlongo P, Mannermaa A, Bolla MK, Wang Q, Dennis J, Ahearn T, et al. Journal article Shared heritability and functional enrichment across six solid cancers (2019) Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, et al. Journal article Awareness of breast cancer incidence and risk factors among healthy women in Germany: an update after 10 years (2019) Poehls UG, Hack C, Wunderle M, Renner SP, Lux MP, Beckmann M, Fasching P, Nabieva N Journal article Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations (2019) Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al. Conference contribution